Incyte has strengthened its Inflammation and Autoimmunity pipeline by acquiring Escient Pharmaceuticals. The acquisition brings EP262 and EP547, two oral MRGPR antagonists, into Incyte’s portfolio.
EP262 targets MRGPRX2, a receptor found on mast cells. By blocking its activation, EP262 aims to treat mast cell-mediated diseases such as chronic inducible urticaria, chronic spontaneous urticaria, and atopic dermatitis. Preclinical studies suggest its potential to alleviate symptoms associated with these conditions.
EP547, on the other hand, is designed to inhibit MRGPRX4, a receptor involved in severe pruritus. Its potential applications include treating cholestatic pruritus and other conditions characterized by extreme itching.
Incyte’s commitment to addressing unmet patient needs drives this acquisition. The company believes that Escient’s innovative candidates have the potential to revolutionize the treatment of inflammatory diseases.
The acquisition demonstrates Incyte’s recognition of the value of Escient’s research and development efforts. Escient’s team had significantly advanced in understanding MRGPR biology and developing novel therapies. The transition to Incyte positions these therapies to reach a broader patient population globally, enabling access to potential treatments that can alleviate suffering and improve quality of life.
Source link: http://www.businesswire.com/news/home/20240530903016/en/Incyte-Completes-Acquisition-of-Escient-Pharmaceuticals
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
